PURPOSEWe prospectively treated patients with hepatitis C virus (HCV)-associated indolent lymphomas with genotype-appropriate direct-acting antivirals (DAAs) with the aim to evaluate virologic and hematologic outcomes. No prospective studies in this setting have been published so far.METHODSFIL-BArT is a prospective, multicenter, phase II trial that evaluated genotype-appropriate DAAs in untreated HCV-positive patients with indolent lymphomas without criteria for immediate conventional antilymphoma treatment. The primary objective was sustained virologic response, whereas the main secondary objectives were overall response rate of lymphoma and progression-free survival.RESULTSForty patients were enrolled, including 27 with marginal zone lymphoma. Median age was 68 years. Extranodal sites were involved in 14 cases (35%). Main genotypes were 1 in 16 patients and 2 in 21 patients. All patients received genotype-guided DAAs: 17 ledipasvir/sofosbuvir, eight sofosbuvir plus ribavirin, and 15 sofosbuvir/velpatasvir. All patients achieved sustained virologic response (100%). DAAs were well tolerated, with only two grade 3-4 adverse events. Overall response rate of lymphoma was 45%, including eight patients (20%) achieving complete response and 10 (25%) partial response, whereas 16 exhibited stable disease and six progressed. With a median follow-up of 37 months, two patients died (3-year overall survival 93%; 95% CI, 74 to 98) and three additional patients progressed, with a 3-year progression-free survival of 76% (95% CI, 57 to 87).CONCLUSIONHCV eradication by DAAs was achieved in 100% of HCV-positive patients with indolent lymphomas not requiring immediate conventional treatment and resulted in non-negligible rate of lymphoma responses. Treatment with DAAs should be considered as the first-line therapy in this setting.

Direct-Acting Antivirals as Primary Treatment for Hepatitis C Virus-Associated Indolent Non-Hodgkin Lymphomas: The BArT Study of the Fondazione Italiana Linfomi / Merli, M.; Rattotti, S.; Spina, M.; Re, F.; Motta, M.; Piazza, F.; Orsucci, L.; Ferreri, A. J. M.; Perbellini, O.; Dodero, A.; Vallisa, D.; Pulsoni, A.; Santoro, A.; Sacchi, P.; Zuccaro, V.; Chimienti, E.; Russo, F.; Visco, C.; Zignego, A. L.; Marcheselli, L.; Passamonti, F.; Luminari, S.; Paulli, M.; Bruno, R.; Arcaini, L.. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - 384:(2022), pp. N/A-N/A. [10.1200/JCO.22.00668]

Direct-Acting Antivirals as Primary Treatment for Hepatitis C Virus-Associated Indolent Non-Hodgkin Lymphomas: The BArT Study of the Fondazione Italiana Linfomi

Luminari S.;
2022

Abstract

PURPOSEWe prospectively treated patients with hepatitis C virus (HCV)-associated indolent lymphomas with genotype-appropriate direct-acting antivirals (DAAs) with the aim to evaluate virologic and hematologic outcomes. No prospective studies in this setting have been published so far.METHODSFIL-BArT is a prospective, multicenter, phase II trial that evaluated genotype-appropriate DAAs in untreated HCV-positive patients with indolent lymphomas without criteria for immediate conventional antilymphoma treatment. The primary objective was sustained virologic response, whereas the main secondary objectives were overall response rate of lymphoma and progression-free survival.RESULTSForty patients were enrolled, including 27 with marginal zone lymphoma. Median age was 68 years. Extranodal sites were involved in 14 cases (35%). Main genotypes were 1 in 16 patients and 2 in 21 patients. All patients received genotype-guided DAAs: 17 ledipasvir/sofosbuvir, eight sofosbuvir plus ribavirin, and 15 sofosbuvir/velpatasvir. All patients achieved sustained virologic response (100%). DAAs were well tolerated, with only two grade 3-4 adverse events. Overall response rate of lymphoma was 45%, including eight patients (20%) achieving complete response and 10 (25%) partial response, whereas 16 exhibited stable disease and six progressed. With a median follow-up of 37 months, two patients died (3-year overall survival 93%; 95% CI, 74 to 98) and three additional patients progressed, with a 3-year progression-free survival of 76% (95% CI, 57 to 87).CONCLUSIONHCV eradication by DAAs was achieved in 100% of HCV-positive patients with indolent lymphomas not requiring immediate conventional treatment and resulted in non-negligible rate of lymphoma responses. Treatment with DAAs should be considered as the first-line therapy in this setting.
384
N/A
N/A
Direct-Acting Antivirals as Primary Treatment for Hepatitis C Virus-Associated Indolent Non-Hodgkin Lymphomas: The BArT Study of the Fondazione Italiana Linfomi / Merli, M.; Rattotti, S.; Spina, M.; Re, F.; Motta, M.; Piazza, F.; Orsucci, L.; Ferreri, A. J. M.; Perbellini, O.; Dodero, A.; Vallisa, D.; Pulsoni, A.; Santoro, A.; Sacchi, P.; Zuccaro, V.; Chimienti, E.; Russo, F.; Visco, C.; Zignego, A. L.; Marcheselli, L.; Passamonti, F.; Luminari, S.; Paulli, M.; Bruno, R.; Arcaini, L.. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - 384:(2022), pp. N/A-N/A. [10.1200/JCO.22.00668]
Merli, M.; Rattotti, S.; Spina, M.; Re, F.; Motta, M.; Piazza, F.; Orsucci, L.; Ferreri, A. J. M.; Perbellini, O.; Dodero, A.; Vallisa, D.; Pulsoni, A.; Santoro, A.; Sacchi, P.; Zuccaro, V.; Chimienti, E.; Russo, F.; Visco, C.; Zignego, A. L.; Marcheselli, L.; Passamonti, F.; Luminari, S.; Paulli, M.; Bruno, R.; Arcaini, L.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1286807
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? ND
social impact